Impact of COVID Pandemic on Cancer Care: Cross-sectional Scenario of an Indian State (Bihar)

  1. Avik Mandal ,
  2. Pritanjali Singh ,
  3. Dharmendra Singh ,
  4. Manika Verma ,
  5. Amrita Rakesh

Vol 6 No S1 (2021): Oncology Practices amid COVID-19 Pandemic

DOI 10.31557/apjcc.2021.6.S1.27-33


Introduction: World Health Organization declared the novel coronavirus (COVID-19) outbreak as pandemic on March 11th 2019. Since then, it has massive impact on public health and economy. Various measures including lock-down, social distancing and massive vaccination drive are implemented globally to curb the spread of the pandemic.
Objective: The study is conducted to analyse the demography and census of the patients attending department of radiotherapy, All India Institute of Medical Sciences (AIIMS), Patna during the first wave hit of COVID-19 pandemic in 2019 to assess the impact of this pandemic on cancer care.
Methods and materials: Census data was retrieved digitally from 1st January 2019 to 15th June 2019 from Hospital Information system. We analyzed the visit of cancer patients to the day care chemotherapy unit, out patient department, and hospital admission and compared the data between pre-lockdown and post-lockdown periods.
Results: A total of 1175 patients with malignancy visited department of radiotherapy from 1st January to 23rd March 2019. After the lock down announcement of nationwide lock down the total number of patient visiting to radiotherapy department dropped to 445 patients. This decrease is not significantly correlating with age group of patients (age < 18 years, 18-70 years and >70 years). Between 24th March and 15th June,123 patients were screened for SARS-CoV-2 patients before hospital admissions, three of them found to be positive for SARS-CoV-2 and were shifted to COVID ward. Distance of the affected district from the care giving hospital has massive impact on cancer care due to restricted logistic.
Conclusion: The cancer care in COVID pandemic is highly dependent on the judicious discretion of the oncologists to maintain the balance between added risk of COVID infection and benefit of treatment modalities. With massive vaccination drive, and effective implementation of lock down of the containment zones, the spread of the pandemic has to be restricted further, with the continuation of ‘new normal’ activities.



World Health Organization (WHO) declared the novel coronavirus disease (COVID-19) outbreak as Public Health Emergency of International Concern (PHEIC) on 30th January 2020 and subsequently declared COVID-19 a pandemic on 11th March 2020. The Nationwide lockdown was announced by Government of India (GOI) on 24th March, 2020 to restrict the movement of a massive 1.3 billion population of the country as a preventive measure against the pandemic. India followed the lockdown in phase-wise manner and, containment for large outbreaks through geographic quarantine or ‘cordon sanitaire’ was carried out in different clusters across the country.

The districts were earlier designated as red-zones (hotspots), orange zones and green zones mainly based on the cumulative positive cases and the doubling rate. As per the notification on 30th April 2020 by the Department of Health and Family Welfare, GOI there were 5 red zones, 20 orange zones and 13 green zones in Bihar and five most affected districts were Patna, Madhubani, Bhagalpur, Begusarai, and Siwan. The prolonged and widespread presence of COVID-19 pandemic globally has severely impacted the delivery of healthcare facility all over the country including the care of cancer patients. The shortfall of adequate health care infrastructure and human resources, vast supply-chain disruptions, and lack of foolproof evidence regarding the transmission, prevention and treatment strategies of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have impeded patient care and safety severely.

The susceptibility of immuno-compromised cancer patients to influenza virus was well known before the emergence of SARS-CoV-2. Influenza increases the risk of hospital admission with severe respiratory distress four times, and the risk of death as 10 times higher when compared with patients without malignancy [1]. In a case study in three hospitals within Wuhan, China twenty-eight cancer patients were observed who were infected with SARS-CoV-2 [2]. Lung carcinoma was the most frequent cancer type in this study and eight patients were suspected to have hospital-associated transmission. If the malignancy related treatment was given within 14 days of developing symptoms, it leads to severe respiratory events. 53.6% of patients in this study were found to have severe events and the mortality rate was 28.6%. Several cancer centres globally have drastically reduced their services after this preliminary report from China came out. Although several international consensus guidelines are developed to steer the cancer care in the pandemic situation, it is an enormous dilemma for oncologists to decide what is best for their patients and the healthcare workers (HCW) and to keep the balance between risks and benefits of the treatment [3,4].

In this study, we analysed the characteristics of the cancer patients including demography, diagnosis, and distance from the hospital during the first wave in 2020 months to know the impact of COVID pandemic on cancer care in the hospital as well as in the State.

Materials and Methods

We retrieved the cancer patient data digitally from the Hospital information system (HIS) since 1st January 2020 to 15th June 2020 and compared the census between pre-lockdown (1st January to 23rd March) and post lockdown (24th March to 15th June) periods. The number of cancer patients visiting radiotherapy OPD, Flu clinic, daycare chemotherapy centre, and the number of admitted patients in IPD in this time duration are tabulated and analysed. The number of the patients from all thirty-eight districts of Bihar are analysed and the patient pool as per the average distance from the AIIMS Patna was also analysed in pre and post lockdown period.

Standard operating procedure (SOP) for the movement of the patient

In our institute, we maintained a strict SOP to prevent the spread of COVID-19 among the HCW, and other patients who are already vulnerable or suffering from multiple co-morbidities. HCW in the hospital were provided with adequate Personal Protective Equipments (PPE) as per the guidelines laid by Ministry of Health and Family Welfare, GOI [5]. The SOP for the movement of the cancer patient who visited our department during the COVID-19 pandemic is illustrated in Figure 1.

Figure 1. Departmental Standard Operating Procedure (SOP) for the Movement of the Patient.

Diagnostic test for SARS-CoV-2

All the patients who required admission in IPD underwent mandatory testing for SARS-CoV-2 by both nasopharyngeal and oropharyngeal swab and remained in holding wards till their report were prepared before transfer to IPD building to keep the IPD section sterile from the COVID infection. At our institute, we performed qualitative Real time transcriptase - polymerase reaction (RT-PCR) to detect RNA of SARS-CoV-2.

‘AIIMS PATNA SWASTHYA’ Mobile Application

This mobile app provides eConsultancy for the patients, registered at AIIMS Patna who can raise a request for telemedicine advice through the application and can view reports of laboratory investigations, department wise consultation schedule and tariffs. The department of Radiotherapy has started providing registration and telemedicine support to the cancer patients as well.

Difficulty in diagnosis and staging of cancer patients in COVID era

Most forms of endoscopy, particularly bronchoscopy, upper gastrointestinal endoscopy, nasopharyngoscopy, direct and indirect laryngoscopy are classified as aerosol-generating procedure (AGP), which increases the risk of SARS-CoV-2 transmission. Colonoscopy also carries risk due to the fecal shedding of the virus. British Society of Gastroenterology and Joint Advisory Group has recommended to carry out only therapeutic emergency and essential endoscopy and has put endoscopy for cancer staging and treatment planning as “Need discussion (Case-by-case)” category [6]. There has been a consensus among the American College of Gastroenterology, European Society of Gastrointestinal Endoscopy and the Asian Pacific Society for Digestive Endoscopy that all elective endoscopies should be suspended [7]. As a result, availability of different endoscopic services has been markedly decreased across the world leading to less number of cancer detection and delayed staging. On the contrary, demand for non-invasive imaging like computed tomography has increased, as it carries a lower risk of contamination.

Capacity for surgery has also been reduced amid the challenging and uncertain times of pandemic and mechanical ventilators have been kept reserved to provide additional critical care capacity for patients affected with COVID-19. The American College of Surgeons (ACS) has recommended that semi-elective surgeries, such as in incompletely obstructing colon cancers, esophageal stenting for malignant growth and surgeries for most gynaecological cancers should continue in the early stages of the pandemic and only emergency surgeries, like intervention in perforated, completely obstructed or actively bleeding cancers should be executed around the peak of the pandemic [8].

Due to the near-total lockdown for prolonged duration, there is an extreme bottleneck in public transportation in India. As a result, much fewer footfalls are observed in the healthcare facilities in the country. Furthermore, many cancer patients have been fearful of exposure to SARS-CoV-2 and have been less likely to present to hospitals for diagnostic workup leading to considerable delay in staging and more incidence of advanced presentation in ED with various acute medical and surgical conditions.

Triage of cancer patients for chemotherapy

Systemic chemotherapy may expose patients to a higher risk of becoming infected and may lead to worse outcomes once they incur COVID-19. Treatment with systemic chemotherapies should be decided on a case-by- case basis considering the following factors [9]. However, the treating oncologist should always keep in mind the risk of disease progression or increased rate of emergency admissions with medical and surgical complications.

1. Intent of the treatment and risk-benefit ratio associated with systemic chemotherapies should be judged meticulously. When the chemotherapy is associated with excellent improvement in outcomes, as for small-cell lung cancer or many acute hematological malignancies, there is consensus that the cycles of chemotherapy must continue. However, when the absolute benefit of chemotherapy is marginal, such as in the case of palliative chemotherapy or adjuvant for elderly and co-morbid patients, treatment may be postponed or alternative treatment options should be explored.

2. Less resource-intensive treatment regimes with a similar range of efficacy and lesser toxicity.

3. Level of immune-suppression associated with an individual chemotherapy regime. Age over 60 years, patients with pre-existing cardiovascular and respiratory disease are already vulnerable and more prone to developing severe manifestations if get infected with SARS-CoV-2.

4. Distance from the hospital and availability of transportation

5. Availability of local health care facilities in case of medical and surgical emergencies.

Considering these factors, we may categorise the cancer patients as per different priority level [10]. We took the decision of giving chemotherapies in our institute mostly on the priority level as illustrated in Table 1.

Table 1. Categorisation of Patients as Per the Priority Level During COVID-19 Pandemic.

Priority level Criteria Examples
Level 1 Curative therapy with >50% chance of success. If NACT€ or adjuvant chemotherapy can increase at least 50% chance of cure to surgery or RTƳ alone or treatment is given at relapse Early breast cancer, Germ cell tumor of Ovary, Seminoma
Level 2 Curative therapy with 20- 50% chance of success. If NACT or adjuvant therapy can increase 20 – 50% chance of cure to surgery or RT alone or treatment is given at relapse Medulloblastoma standard risks, Carcinoma Larynx, Stage III NSCLC¥
Level 3 Curative therapy with only 10 – 20% of success If NACT or adjuvant chemotherapy can increase 10 – 20% chance of cure to surgery or RT alone or treatment is given at relapse. Non-curative therapy with >50% chance of >1 year of life expectancy. Locally advanced gastric carcinoma, Locally advance Carcinoma Gall bladder
Level 4 Curative therapy with 0-10% chance of success. If NACT or adjuvant chemotherapy increases less than 10% chance of cure to surgery or RT alone or treatment is given at relapse Non-curative therapy with 15-50% chance of > 1 year life extension. Hepatocellular carcinoma, not a candidate for transplant
Level 5 Non-curative therapy with >50% chance of palliation or temporary tumour control but < 1 year life extension Palliative chemotherapies, Supportive treatment
Level 6 Non-curative therapy with 15-50% chance of palliation or temporary tumour control and < 1 year life extension Palliative chemotherapies, Supportive treatment, Best supportive treatment, Hospice

Abbreviations, Neoadjuvant chemotherapy; ƳRadiotherapy; ¥ Non small cell carcinoma lung


After analyzing the data which we retrieved digitally from the HIS since 1st January 2020 to 15th June 2020, we found a significant decrease in the number of total visits of the patients (footfalls) in OPD and IPD, the absolute number of patients both newly registered and follow-up cases, after the announcement of lockdown in the country. Total visits in the department of Radiotherapy, AIIMS Patna was 2920 times by 1175 cancer patients from 1st January 2020 to 23rd March 2020. After the announcement of nationwide lock-down the number of visits dropped to 1038 times by 445 patients from 24th March 2020 to 15th June 2020. Though, no significant correlation was found in the vulnerable age groups (<18 years and >70 years) with the percentage of decrease in post-lockdown period. The detail of the census of the cancer patients in the pre and post lockdown period is tabulated in (Table 2) (Table 3) and (Table 4).

Table 2. Analysis of Patient Characteristics Including Demography, Diagnosis and Census in Pre and Post Lockdown Period.

    Pre-Lockdown   Post-Lockdown  
    Count Table N (%) Count Table N (%)
Age group Up to 18 years 72 6.1 32 7.2
  > 18 - 30 years 108 9.2 35 7.9
  31 - 50 years 453 38.6 190 42.7
  51 - 70 years 485 41.3 169 38
  > 70 years 57 4.9 19 4.3
Sex Male 515 43.8 181 40.7
  Female 660 56.2 264 59.3
Bihar / Other State Other State 23 2 8 1.8
  Bihar 1152 98 437 98.2
Diagnosis of patients attending OPD∑ Breast malignancy 233 19.8 99 22.2
  Gastrointestinal malignancy 311 26.5 124 27.9
  Genitourinary malignancy 204 17.4 77 17.3
  Head and neck malignancy, CNS Tumours 260 22.1 65 14.6
  Lung malignancy 76 6.5 42 9.4
  Paediatric malignancy 60 5.1 16 3.6
  Soft tissue Sarcoma 31 2.6 22 4.9
Total number of daycare admission     465   351
Total number of IPD£ admission     279   123
Total number of cancer patients screened     NIL   123

Abbreviations, Out patient department; £ In patient department

Table 3. Analysis of Patient Population as Per the Distance from the Institute in Pre and Post Lockdown Period.

  Pre-lockdown Post-Lockdown
  Frequency Percent Frequency Percent
50 KM 400 34 154 34.6
51 - 100 KM 298 25.4 123 27.6
101 - 150 KM 316 26.9 110 24.7
151 - 200 KM 61 5.2 24 5.4
201 - 250 KM 43 3.7 17 3.8
> 251 KM 57 4.9 17 3.8
Total 1175 100 445 100

Table 4. Analysis of District Wise Census of Cancer Patients in Pre and Post Lockdown Period. Districts are Classified in Terms of Total Covid Positive Cases of at the Time of Writing of this Article.

Number Percentage Number Percentage
Other States 23 2 8 1.8
Low risk districts Araria 9 0.8 6 1.3
Arwal 16 1.4 3 0.7
Jamui 16 1.4 8 1.8
Lakhisarai 8 0.7 2 0.4
Seohar 0 0 0 0
Medium risk districts Aurangabad 21 1.8 5 1.1
Banka 4 0.3 1 0.2
Bhojpur 57 4.9 24 5.4
Buxar 22 1.9 5 1.1
Darbhanga 20 1.7 9 2
East Champaran 31 2.6 17 3.8
Gaya 39 3.3 10 2.2
Gopalganj 20 1.7 6 1.3
Jehanabad 20 1.7 4 0.9
Kaimur 2 0.2 0 0
Katihar 15 1.3 5 1.1
Khagaria 18 1.5 10 2.2
Kishanganj 2 0.2 1 0.2
Madhepura 13 1.1 2 0.4
Munger 22 1.9 8 1.8
Muzaffarpur 48 4.1 21 4.7
Nalanda 39 3.3 27 6.1
Nawada 15 1.3 3 0.7
Purnia 16 1.4 3 0.7
Rohtas 18 1.5 5 1.1
Saharsa 19 1.6 6 1.3
Samastipur 39 3.3 15 3.4
Saran 75 6.4 33 7.4
Seikhpura 8 0.7 2 0.4
Sitamarhi 26 2.2 6 1.3
Supaul 11 0.9 3 0.7
Vaishali 60 5.1 22 4.9
West Champaran 16 1.4 8 1.8
High risk districts Begusarai 29 2.5 9 2
Bhagalpur 15 1.3 6 1.3
Madhubani 22 1.9 8 1.8
Patna 320 27.2 128 28.8
Siwan 30 2.6 9 2
Total 1175 100 445 100

Total of 123 patients was screened for infection with SARS-CoV-2 regardless of their symptoms and travel history before admission in IPD. Out of 123 patients, 3 patients were found positive for SARS-CoV-2 and were shifted to COVID ward. Two positive patients were female; both were with diagnosis of carcinoma ovary and the male patient was diagnosed with carcinoma lung. Two of them were not our registered follow-up case and had recent inter-state travel history. One of the female patients had severe COVID related events and succumbed in the intensive care unit with respiratory failure.


The COVID-19 pandemic has changed many of our perspectives including our social behaviours and way of living. The actual impact of the pandemic of this unprecedented scale actually can be fathomed only after it gets normalised. The healthcare system of many countries was nearly collapsed and required extensive support and resources for the restoration. The cancer care globally is no exception to suffer worst hit by the pandemic [11-13] With our retrospective study of the census of cancer patients of our institute particularly during the first wave of COVID-19 pandemic, we analysed several aspects of cancer care including the demographic distribution and overall impact of pandemic on the cancer care in the state. With slightly increased female: male ratio in the post lockdown era, we may observe that, there is apparently no domestic and social discrimination towards the female cancer patients in the time of economic and logistic crisis. In a society, where injustice and apathy are very common towards women and particularly towards the female cancer patients, this finding can be interpreted as a silver lining on the background of worrying gender discrimination in the country.

Similarly, the paediatrics age group (<18 years) and advanced age group (>70 years) follow almost similar percentage of the patient population in the pre and post lockdown era which might broadly reflect domestic and social attention towards them as well. Although, this is a single institute observation, these findings may be taken into consideration to infuse some positivity in our mind in this difficult time of crisis and adversity.

The number of cancer patients who visit our hospital from the neighbouring states and the country (particularly Nepal) has been reduced drastically due to the restricted transportation in the country. Though the number of the patients with incomplete treatment at other centres outside the state, increased gradually in our hospital after the beginning of unlocking.

In spite of the fact that the rank of the districts is inter-changing in terms of active cases over the course of pandemic, Patna remained as the topmost affected district in Bihar. After the announcement of lockdown on 24th March 2020, there was 60% decrease in patient population from Patna, the district where our institute itself is situated. We experienced a decrease in the tune of 70-60% of patient pool from the other top five affected districts as well namely Siwan, Madhubani, Begusarai and Bhagalpur. The massive impact of lock-down on the public transportation and overall socio-economic disruption lead to such a significant drop of the visits of the cancer patients. Unfortunately, a striking number of patients who need palliative and supportive care would lose their lives without proper intervention in this pandemic [14]. Many centres including us are continuing the systemic chemotherapies with curative intent during the pandemic. With the mandatory screening protocol before admission, we find 2.4% COVID positivity rate among the cancer patients (including those who returned from the other states). No patient with ongoing systemic chemotherapies was found with influenza like illness (ILI) or Severe acute respiratory infection (SARI).


Based on the observations made by the several international consensus guidelines, we adopted the following strategies to balance between risk and benefits of continuing treatment of our patients in the COVID-19 pandemic:

• Changing intravenous regimes to subcutaneous or oral if expected outcome is within similar range but with lesser toxicity. For example we introduced Tablet Capecitabine based regimen (CapOx) instead of infusion Injection 5-Fluorouracil (5-FU).

• Selecting regimens that are shorter in duration which can be administered in day-care facility.

• Considering 4-weekly or 6-weekly immunotherapy regimens rather than 2-weekly and 3-weekly protocol.

• Avoid dose-dense chemotherapy regime for the treatment of carcinoma breast. Avoid Injection Gemcitabine every weekly cycle.

• Radiotherapy can be given to replace or to delay other treatment modalities which carry higher infection risk. For example a short course of radiotherapy can be used to delay surgery in patients with rectal carcinoma.

• Prescribe oral routine medicines for the duration of a month where possible to minimise patient exposure in OPD.

• Consider deferring supportive therapies such as Injection denosoumab and Injection zoledronic acid administration.

• Use of Granulocyte colony-stimulating factor (G-CSF) as prophylaxis to reduce the incidence of febrile neutropenia and related admission.

• Considering treatment breaks for long-term treatments (Drug Holiday), for example in carcinoma prostate.

• General measures across all services and facilities to reduce patient contact and maximise workforce capacity. To cut non-essential follow-up visits, reduce stay time in hospital.

• Minimise face-to-face interactions, increase consultations via telephone or video consultation. We have introduced a mobile application, ‘AIIMS PATNA SWASTHYA’ aiming reduced footfall in the hospital.

In conclusion, the cancer care in COVID pandemic is highly dependent on the judicious discretion of the oncologists who are responsible to maintain the balance between the added risk of infection and the benefits of the treatment modalities. Systemic chemotherapies can safely be administered to the cancer patients after the proper screening and triage, especially when the chance of cure is considerable. Available vaccines against COVID19 are also found safe and effective for patients with malignancy [15,16]. The constraints in logistics and disrupted economic factors might play a bigger role in healthcare as well as in the care of cancer patients. With the anticipation of further waves of SARS-CoV-2, we must be better prepared to provide adequate care to the ‘vulnerable’ cancer patients and policy makers of the country should judiciously implement restrictions whenever required to curb the peak of the infection. But logistics support for the cancer patients should be ensured, so that screening, new diagnosis, ongoing therapy as well as follow up visits remain continue full fledged in the hospitals. With successful vaccination drive, and effective implementation of lock down of the containment zones, the spread of the pandemic has to be restricted further, with the continuation of ‘new normal’ activities.


We would like to acknowledge the contribution of all the staff of the department of Radiotherapy, AIIMS Patna who are working tirelessly on the frontline in the battle against COVID-19.

Conflict of interest



  1. Influenza vaccines in immunosuppressed adults with cancer Bitterman Roni, Eliakim-Raz Noa, Vinograd Inbal, Zalmanovici Trestioreanu Anca, Leibovici Leonard, Paul Mical. Cochrane Database of Systematic Reviews.2018. CrossRef
  2. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China Zhang L., Zhu F., Xie L., Wang C., Wang J., Chen R., Jia P., Guan H.Q., Peng L., Chen Y., Peng P., Zhang P., Chu Q., Shen Q., Wang Y., Xu S.Y., Zhao J.P., Zhou M.. Annals of Oncology.2020;31(7). CrossRef
  3. Cancer Management in India during Covid-19 Pramesh C.S., Badwe Rajendra A.. New England Journal of Medicine.2020;382(20). CrossRef
  4. COVID-19 Useful Resources | ESMO. Accessed July 27, 2020..
  5. Ministry of Health and Family Welfare Directorate General of Health Services [Emergency Medical Relief] Novel Coronavirus Disease 2019 (COVID-19): Guidelines on Rational Use of Personal Protective Equipment .
  6. Endoscopy activity and COVID-19: BSG and JAG guidance | The British Society of Gastroenterology Accessed July 27, 2020..
  7. Joint ACPGBI, BSG and BSGAR considerations for adapting the rapid access colorectoral cancer pathway during COVID-19 pandemic | The British Society of Gastroenterology Accessed June 17, 2020..
  8. COVID-19: Elective Case Triage Guidelines for Surgical Care Accessed June 18, 2020..
  9. Managing cancer patients during the COVID-19 pandemic management-during-the-covid-19-pandemic/consensus- recommendations-managing-cancer-patients-during-the- covid-19-pandemic. Accessed August 13, 2021..
  10. Specialty Guides for Patient Management during the Coronavirus Pandemic https://assets.publishing.service. data/file/869827/Coro. Accessed June 22, 2020..
  11. The impact of the COVID-19 pandemic on cancer care Richards Mike, Anderson Michael, Carter Paul, Ebert Benjamin L., Mossialos Elias. Nature Cancer.2020;1(6). CrossRef
  12. Impact of nationwide lockdown on cancer care during COVID-19 pandemic: A retrospective analysis from western India Pareek Ananya, Patel Apurva A., Harshavardhan A., Kuttikat Philip G., Pendse Shantanu, Dhyani Aruj, Sharma Satish, Agarwal Nikesh, Maji Debajyoti, Reddy Ramidi G., Gupta Yuganshu, Panchal Harsha P., Parikh Sonia. Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021;15(4). CrossRef
  13. Preparedness of the cancer hospitals and changes in oncosurgical practices during COVID‐19 pandemic in India: A cross‐sectional study Singh Hemant Kumar, Patil Vijayraj, Chaitanya Ganne, Nair Deepa. Journal of Surgical Oncology.2020;122(7). CrossRef
  14. Patterns of Care of Gallbladder Cancer During the COVID-19 Pandemic: An Experience of Tertiary Care Centre at Patna, India Singh Dharmendra, Singh Pritanjali, Mandal Avik, Rakesh Amrita, Verma Manika. Asian Pacific Journal of Cancer Care.2020;5(S1). CrossRef
  15. Vaccination of cancer patients against COVID-19: towards the end of a dilemma Mandal Avik, Singh Pritanjali, Samaddar Arghadip, Singh Dharmendra, Verma Manika, Rakesh Amrita, Ranjan Rakesh. Medical Oncology.2021;38(8). CrossRef
  16. The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate Garassino M, Vyas M, de Vries E, Kanesvaran R, Giuliani R, Peters S. Annals of Oncology.2021;32(5):579-581.


© Asian Pacific Journal of Cancer Care , 2021

Author Details

Avik Mandal
<p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p> <p><strong>Personal Informations:</strong></p> <p><strong>&nbsp;</strong></p> <p><strong>Name </strong>: Dr. Avik Mandal</p> <p>Date of Birth: 02/05/1988</p> <p>Present Address: Bhagwati Complex, Vrindavan colony, Road no1, Walmi, PhulwariSarif, Patna 801505</p> <p>Permanent&nbsp; Address: Om Tower, Flat 2C, 36C.BT Road, Kolkata 700002</p> <p>Email: <a href=""></a>&nbsp;&nbsp;&nbsp; Mobile: +91- 9903097254</p> <p><strong>&nbsp;</strong></p> <p><strong>Career Objectives:</strong></p> <p>To be part of a reputed institute as Junior Consultant in the faculty of Radiation oncology that will provide me the opportunity to put my skills in oncology to its best use and to serve cancer patients with utmost care and in turn to develop my academic and clinical skill through the working opportunities of that institute.</p> <p>&nbsp;</p> <p><strong>Educational Qualification</strong>:</p> <p>&nbsp;<strong>MBBS, DMRT, DNB (Radiation oncology) </strong></p> <p><strong>&nbsp;</strong></p> <p><strong>Institute and Year of passing MBBS</strong>: North Bengal Medical College &amp; Hospital in 2010.</p> <p><strong>&nbsp;</strong></p> <p><strong>Year of completion of Internship</strong>: 2011 from North Bengal Medical College</p> <p><strong>&nbsp;</strong></p> <p><strong>Institute and Year of passing DMRT </strong>: IPGMER &amp; SSKM Hospital , Kolkata &nbsp;in 2015</p> <p><strong>&nbsp;</strong></p> <p><strong>Institute and Year of passing DNB (radiation oncology): </strong>Rajiv Gandhi Cancer Institute &amp; Research Centre, Delhi in 2018</p> <p><strong>&nbsp;</strong></p> <p><strong>Present academic and work experience</strong>:&nbsp;&nbsp;</p> <p>Senior Resident in Department of Radiation Oncology at AIIMS, Patna Since February 2019 to till date.</p> <p><strong>Previous</strong> <strong>academic and work experience</strong>:&nbsp;&nbsp;</p> <p>Senior Resident in Department of Radiation Oncology at Batra Hospital &amp; Medical research centre, New Delhi from November 2018 to February 2019.</p> <p><strong>PROFESSIONAL EXPERIENCE</strong></p> <p>Well trained in CT based planning, and contouring both on <strong>Monaco</strong> and <strong>Eclipse </strong>&nbsp;software, performing plan execution, Online and Off line Matching of the images and treating patients with state of the art technologies <strong>3-DCRT/IMRT/IGRT/VMAT </strong>by <strong>TRUEBEAM, ELEKTA and CLINAC </strong>Medical Linear accelerators<strong>.</strong></p> <p><strong>&nbsp;</strong></p> <p>Also have experience in <strong>manual/2-D planning</strong> by X-ray Simulator and treating patients and planning and delivering procedures like <strong>ICRT, ILRT </strong>and <strong>Interstitial brachytherapy</strong> by HDR Brachytherapy (<strong>Microselectron HDR</strong>).</p> <p>&nbsp;</p> <p>Treating solid malignancies by <strong>chemotherapy &amp; Targeted Therapy</strong> and managing the side effects of systemic treatment.</p> <p>Can &nbsp;handle OPD jobs and Indoor patients and perform counselling to the palliative patient and patient’s family members.</p> <p>Trained in diagnostic and therapeutic pleural and ascitic tapping, handling of oncological emergencies etc.</p> <p>&nbsp;</p> <p><strong>Other</strong> <strong>Academic &amp; Clinical Work experience </strong>: &nbsp;</p> <p>A )House staffship in Department of Opthalmology, RG kar Medical College &amp; Hospital, Kolkata for 8 months.</p> <ol> <li>B) House staffship in Department of ENT, RG kar Medical College &amp; Hospital Kolkata for 4 months</li> <li>C) Emergency Medical officer in Institute of neuroscience Kolkata (IN-K) for 2 years</li> </ol> <p><strong>&nbsp;</strong></p> <p><strong>CME and Training Programme Attendance :</strong></p> <ol> <li>12<sup>th</sup> International Conference of the Asian Clinical Oncology Society, New Delhi</li> <li>38<sup>th</sup> Annual Conference of AROI, Bhubaneswar.</li> <li>25<sup>th</sup> ICRO PG Teaching course Program on “ Update on Uro-Genital Malignancies”, Dehradun.</li> <li>16<sup>th</sup> Annual International Conference organized by Rajiv Gandhi Cancer Institute &amp; Research Centre, Delhi.</li> <li>17<sup>th</sup> Annual International Conference organized by Rajiv Gandhi Cancer Institute &amp; Research Centre</li> <li>Clinical Physics for Clinical Oncologists 2018 by Max Superspeciality Hospital, Vaishali.</li> <li>DNB short course clinical classes organized by Multiple institutes in Delhi-NCR</li> <li>FRCR Training Programme by international faculties organized by Tata Medical Center, Kolkata</li> </ol> <p><strong>Publications:</strong></p> <p>&nbsp;</p> <ol> <li>Mandal A, Singh P, Bera S, et al. Set-up Errors and Determination of Planning Target Volume Margins Protocol for Different Anatomical Sites in a Newly Established Tertiary Radiotherapy Centre in India. <em>Asian J Oncol</em>. 2020;6:81-7.</li> <li>Singh D, Mandal A. The prognostic value of lymph node ratio in survival of non-metastatic breast carcinoma patients. <em>Breast Cancer Res Treat</em>. 2020.</li> <li>Singh D, Singh P, Mandal A, Rakesh A, Verma M. <em>Patterns of Care of Gallbladder Cancer During the COVID-19 Pandemic: An Experience of Tertiary Care Centre at Patna, India</em>. Vol 5.; S2, 51-7;2020.</li> <li>Sumit P, Manish S, Avik M, Arvind P. To Evaluate and Compare the Dosimetric Effects of Deep Inspiratory Breath-Hold Technique with Free Breathing Technique With Respect To Target Coverage and Organs at Risk in Patients of Left Sided Breast Cancer Treated By External Beam Radiotherapy. <em>Int J Res Rev Vol</em>. 2019;6.</li> <li>Singh D, Singh P. <em>Epidemiology and Treatment Outcomes of Testicular Germ Cell Tumor at Tertiary Care Center in Patna, India: A Retrospective Analysis</em>. Vol 5.; 2020.</li> <li>Mitra S, Kumar Sharma M, Kaur I, et al. Vulvar carcinoma: Dilemma, debates, and decisions. <em>Cancer Manag Res</em>. 2018;10:61-8.</li> <li>Mitra S, Ahlawat P, Sharma M, et al. Rising Incidence of Rectal Carcinoma in the Young Age"Is it A Concern? An Indian Perspective. <em>J Cancer Prev Curr Res</em>. 1971.</li> <li>Tandon S, Gairola M, Pal M, et al. The use of adaptive intensity-modulated radiotherapy in the treatment of small-cell carcinoma lung refractory to chemotherapy in a patient with preexisting interstitial lung disease. <em>Lung India</em>. 2018;35:54-7.</li> <li>Avik Mandal, S Mitra, M.K. Sharma, P. Ahlawat, I. Kaur, R Khurana, M. Verma, S. Dutta. Does cervical adenocarcinoma carry worser prognosis than squamous variant in patients treated with definitive chemoradiation: A retrospective study.[Abstract] Gynaecology. J Can Res Ther [serial online] 2016;12:29-43</li> </ol> <p><strong>Prize and Awards:</strong></p> <p>1<sup>st</sup> runner up prize for Best Poster presentation at AROICON-Bihar chapter 2019</p> <p>&nbsp;</p>
All India Institute of Medical Sciences,Patna

Pritanjali Singh
<p><u>Dr. Pritanjali Singh&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p> <p>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p><strong><u>Curriculum Vitae</u></strong></p> <table> <tbody> <tr> <td width="343"> <p><strong><u>Coresspondence address</u></strong></p> <p>13/14, Vandana Appartment, Patliputra Path,</p> <p>Near Telephone&nbsp; exchange,</p> <p>Rajendra Nagar,Patna-800016</p> <p><strong>Phone:</strong>&nbsp; 91-9334931395</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 91- 9835066460</p> </td> <td width="343"> <p><strong><u>Permanent Address :</u></strong></p> <p>&nbsp;2M/106, Bahadurpur Housing Colony,</p> <p>&nbsp;Kankarbagh Patna-800020.</p> <p><strong>&nbsp;Phone :</strong> 91-612-2353993</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;91-612-2368050</p> <p><strong>&nbsp;Mobile :</strong> 91-9334931395</p> <p>&nbsp;</p> </td> </tr> </tbody> </table> <p><strong><u>&nbsp;</u></strong></p> <p><strong>&nbsp;EMAIL ID&nbsp;&nbsp;&nbsp; </strong><a href=""><strong></strong></a></p> <p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><a href=""><strong></strong></a></p> <p><strong>&nbsp;</strong></p> <p>&nbsp;</p> <p><strong><u>Personal Details</u></strong>:</p> <p>&nbsp;</p> <p><strong>Father’s Name</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; :&nbsp; Dr. Ravindra Narain Singh.</p> <p>&nbsp;</p> <p><strong>Spouse’s Name</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; :&nbsp; Dr. Vijay Pratap Singh.</p> <p>&nbsp;</p> <p><strong>Date of Birth</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; :&nbsp; 04/01/1973</p> <p>&nbsp;</p> <p><strong>Sex&nbsp;&nbsp; </strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;:&nbsp; Female.</p> <p>&nbsp;</p> <p><strong>Nationality</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;:&nbsp; Indian.</p> <p>&nbsp;</p> <p><strong>Present employment</strong>&nbsp;&nbsp;&nbsp;&nbsp; :&nbsp; &nbsp;&nbsp;Additional Professor &amp; HoD,</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Radiation Oncology,</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All India Institute of Medical Science, Patna.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p><strong><u>ACADEMIC AND PROFESSIONAL QUALIFICATIONS:</u></strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p> <p><strong>&nbsp;</strong></p> <p><strong>1989</strong>&nbsp;&nbsp;&nbsp; <strong>:</strong>&nbsp; High School-St. Joseph’s convent, Patna, Bihar, India</p> <p><strong>1990-1991:</strong> Premedical training-Science College, Patna, Bihar, India.</p> <p>&nbsp;</p> <p><strong>1998:</strong><strong>&nbsp;&nbsp; </strong>Graduate medical training: MBBS.Patna Medical College, Patna University, Patna, Bihar, India.</p> <p>&nbsp;</p> <p><strong><u>&nbsp;</u></strong></p> <p><strong><u>&nbsp;</u></strong></p> <p><strong><u>&nbsp;POSTGRADUATE TRAINING </u></strong></p> <p>&nbsp;</p> <ul> <li>Postgraduate Residency in Radiation Oncology,</li> </ul> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mahavir Cancer Instititute,</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patna, Bihar, India.</p> <p><strong><u>&nbsp;</u></strong></p> <p><strong><u>POST GRADUATE THESIS</u></strong>: Surgery, chemotherapy and radiation in the management of Locally</p> <p>Advanced breast cancer</p> <p><strong><u>&nbsp;</u></strong></p> <p><strong><u>AWARDED</u></strong>: 1) Professional Diploma in Clinical Research August 2007.</p> <p>&nbsp;</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;2) American School For Continuing Medical Education Certificate titled” Review of role of Trastuzumab in the Treatment of HER2 positive Breast cancer”, Oct 2010.</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p><strong><u>&nbsp;PERMANENT REGISTRATION</u></strong>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bihar Medical Council &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Associated body of Medical Council of India)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Registration Number: BMC-31426</p> <p>&nbsp;</p> <p>&nbsp;</p> <p><strong><u>ACADEMIC PERFORMANCE</u></strong></p> <p>&nbsp;</p> <p>PMCH</p> <p><strong>1998</strong>&nbsp;&nbsp;&nbsp; Final MBBS&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seventh rank in a class of 105.</p> <p><strong>1996</strong>&nbsp;&nbsp;&nbsp; Second MBBS&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First rank in a class of 105. (Gold Medalist)</p> <p><strong>1994</strong>&nbsp;&nbsp;&nbsp; First MBBS&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Second rank in a class of 105.</p> <p>&nbsp;</p> <p>&nbsp;</p> <p><strong><u>HONORS AND AWARDS</u></strong></p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p><strong>1994</strong>&nbsp;&nbsp;&nbsp; <strong>Honors in Anatomy, Physiology and Biochemistry.</strong></p> <p><strong>1994&nbsp;&nbsp;&nbsp; Running shield in Physiology for highest marks in university examination.</strong></p> <p><strong>1996&nbsp;&nbsp;&nbsp; Gold Medal for highest aggregate in second MBBS</strong>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p><strong>1996</strong>&nbsp;&nbsp;&nbsp; <strong>Honors in Pathology, Pharmacology, Microbiology, Preventive &amp; Social Medicine and &nbsp;&nbsp;</strong></p> <p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Forensic Medicine.&nbsp;&nbsp;&nbsp; </strong></p> <p><strong>2010&nbsp; &nbsp;&nbsp;Association of Radiation Oncologist of India (AROI) Fellowship awarded.</strong></p> <p><strong>2014 &nbsp;&nbsp;&nbsp;Dr. Arpita Roy Award for excellence in Oncology.</strong></p> <p><strong>2014&nbsp;&nbsp; European Society of Medical Oncology Certification.</strong></p> <p><strong>2015&nbsp;&nbsp; George Mahogany Award by RCOG for contribution in the field of Gynec- Oncology</strong></p> <p><strong>2017 Association of Radiation Oncologist of India ( AROI) Fellowship awarded</strong></p> <p>&nbsp;</p> <p><strong><u>&nbsp;</u></strong></p> <p><strong><u>PROFESSIONAL EXPERIENCE&nbsp;&nbsp;&nbsp;&nbsp; </u></strong></p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p>&nbsp;<strong>1999-2000</strong></p> <p>&nbsp;One year Rotatory Internship.</p> <p>&nbsp;<strong>Patna</strong><strong> Medical College &amp; Hospital, </strong>Patna, India&nbsp;</p> <p>&nbsp;</p> <p><strong>&nbsp;2001</strong></p> <p>&nbsp;Housemanship in medicine (6 months)</p> <p>&nbsp;Nalanda Medical College and Hospital</p> <p><strong>&nbsp;</strong></p> <p><strong>&nbsp;</strong></p> <p><strong>October 2005-Febuary 2006 (5 mn.)</strong></p> <p>&nbsp;Senior Registrar in Radiation Oncology,</p> <p><strong>Mahavir Cancer Sansthan Patna,</strong> <strong>Bihar</strong><strong>, India</strong><strong>.</strong></p> <p><strong>&nbsp;</strong></p> <p>&nbsp;</p> <p><strong>March 2006-September 2007 (19 mn.)</strong></p> <p>Senior Registrar in Radiation Oncology’</p> <p><strong>Tata Memorial Hospital, Mumbai</strong>, India.</p> <p>&nbsp;</p> <p><strong>November2007-November 2008 (12 mn)</strong></p> <p>Junior Consultant in Radiation Oncology</p> <p><strong>Mahavir Cancer Sansthan Patna Bihar, India.</strong></p> <p><strong>&nbsp;</strong></p> <p><strong>December 2008- August 2012</strong></p> <p>Senior Resident,</p> <p><strong>Regional Cancer Centre,</strong></p> <p><strong>Indira Gandhi Institute of Medical Sciences, Patna.</strong></p> <p><strong>&nbsp;</strong></p> <p><strong>August 2012 – June 2013,</strong></p> <p>Assistant Professor,</p> <p><strong>Regional Cancer Centre,</strong></p> <p><strong>Indira Gandhi Institute of Medical Sciences, Patna.</strong></p> <p><strong>&nbsp;</strong></p> <p><strong>&nbsp;</strong></p> <p><strong>June 2013-June 2016</strong></p> <p>Assistant Professor ,</p> <p><strong>Radiation Oncology ,</strong></p> <p><strong>All India Institute of Medical Sciences, Patna.</strong></p> <p><strong>&nbsp;</strong></p> <p><strong>July 2016-June 2019</strong></p> <p>Associate Professor &amp; HoD<strong> ,</strong></p> <p><strong>Radiation Oncology,</strong></p> <p><strong>All India Institute of Medical Sciences , Patna.</strong></p> <p><strong>&nbsp;</strong></p> <p><strong>July 2019-Continuing</strong></p> <p>Additional Professor &amp; HoD,</p> <p><strong>Radiation Oncology,</strong></p> <p><strong>All India Institute of Medical Sciences, Patna.</strong></p> <p><strong>&nbsp;</strong></p> <p><strong>&nbsp;</strong></p> <p><strong>Fellowship AROI In Gynec Oncology at Peter Mac Callum Cancer Center Australia July 2011.</strong></p> <p><strong>Fellowship AROI in GI Malignancies at MD Cancer Center in Houston, USA.9th May -2<sup>nd</sup> June2017. </strong></p> <p><strong>&nbsp;</strong></p> <p><strong>&nbsp;</strong></p> <p><strong>&nbsp;</strong></p> <p><strong><u>WORKSTATIONS HANDLED </u></strong></p> <p><strong>&nbsp;</strong></p> <ul> <li><strong>Hands on experience in conventional, 3DCRT, IMRT, IGRT, SRS, SRT, SBRT techniques</strong></li> <li><strong>EBRT machines</strong> <ul> <li><strong>Varian</strong> <ul> <li><strong>Truebeam (with VMAT, FFF, HD MLC)</strong></li> <li><strong>Clinac IX</strong></li> </ul> </li> <li><strong>Elekta – </strong> <ul> <li><strong>Synergy</strong></li> <li><strong>Infinity with agility</strong></li> <li><strong>Versa HD</strong></li> </ul> </li> <li><strong>Theratron 780C</strong></li> </ul> </li> <li><strong>Brachytherapy</strong> <ul> <li><strong>Nucletron – Micro selectron HDR 18 and 31 channels.</strong></li> </ul> </li> <li><strong>Simulators</strong> <ul> <li><strong>Varian acuity simulator</strong></li> <li><strong>GE CT Simulator -70cm bore size.</strong></li> </ul> </li> <li><strong>Gating – ABC .</strong></li> <li><strong>Contouring stations</strong> <ul> <li><strong>Somavision – Varian</strong></li> <li><strong>FocalSim – Elekta</strong></li> <li><strong>Virtual simulation – Vsim –Siemens</strong></li> <li><strong>Oncentra – for EBRT and Brachy – Nucletron</strong></li> <li><strong>Monaco - Elekta</strong></li> </ul> </li> <li><strong>Treatment planning systems</strong> <ul> <li><strong>Eclipse version 10</strong></li> <li><strong>Oncentra- Master Plan Version 4.7</strong></li> <li><strong>Elekta CMS XIO – version 4.7</strong></li> <li><strong>Plato sunrise</strong></li> <li><strong>Monaco</strong></li> </ul> </li> <li><strong>Record and verifying system</strong> <ul> <li><strong>Mosaiq</strong></li> </ul> </li> </ul> <p><strong>&nbsp;</strong></p> <p><strong>&nbsp;</strong></p> <p><strong><u>&nbsp;Representive Papers:</u></strong></p> <p><strong><u>&nbsp;</u></strong></p> <ol> <li>“Incidence and prevalence of Pediatric Malignancies in Bihar” 38 IAP 2001, Patna.</li> </ol> <p>&nbsp;</p> <ol start="2"> <li>“<strong><em>Pattern of malignancies, Epidemiological profile of gall bladder cancer, hospital&nbsp;&nbsp; based report</em></strong><strong>”,</strong> ISO, Nov.2002, Mumbai.</li> </ol> <p>&nbsp;</p> <ol start="3"> <li>“Dosimetric evaluation of Intracavitary placements in Carcinoma Cervix”, 24 AMPICON, 2003.</li> </ol> <p>&nbsp;</p> <ol start="4"> <li>“Gemcitabine, Cisplatin in Unresectable carcinoma of Urinary Bladder”, SAARC meet, Nepal 2003.</li> </ol> <p>&nbsp;</p> <ol start="5"> <li>“Gemcitabine, Cisplatin in advanced unresectable Hepatocellular carcinoma”, April 2004, RGCH International meet, N. Delhi.</li> </ol> <p>&nbsp;</p> <ol start="6"> <li><strong>“<em>Gemcitabine, Cisplatin in locally advanced carcinoma of Gall Bladder, an MCS Experience</em></strong>,” ISO, Oct.2004, Bangalore.</li> </ol> <p>&nbsp;</p> <p>&nbsp;</p> <ol start="7"> <li>“<strong><em>A comparative study of surgery versus radiotherapy in early cervical cancer”, AGOICON 2005, Patna.</em></strong></li> </ol> <p>&nbsp;</p> <ol start="8"> <li>“<strong><em>Brachytherapy in head and neck cancers, an MCS </em></strong>Experience<em>”, </em><strong>ASCO 2005, Orlando, Florida, USA</strong>.</li> </ol> <p>&nbsp;</p> <ol start="9"> <li>“Prognostic factors in node negative premenopausal Indian women treated with breast conserving surgery without systemic therapy”. Indian Society of Oncology, Patna, 2006.</li> </ol> <p>&nbsp;</p> <ol start="10"> <li><strong><em>Accelerated radiotherapy versus concomittant chemotherapy in advanced head and neck cancers -single institution results</em></strong> has been accepted for presentation in a <strong>poster</strong> session at the <strong>World Cancer Congress of International Union against Cancer to be held in Geneva, Switzerland.2008.</strong> <strong>WCI Mumbai, Oct 2010. </strong></li> </ol> <p><strong>&nbsp;</strong></p> <ol start="11"> <li><strong>International Federation of Head and Neck Oncology, Goa, Oct, 2011.</strong></li> </ol> <p><strong>&nbsp;</strong></p> <ol start="12"> <li><strong>AROI, Jaipur, Nov, 2011.</strong></li> </ol> <p><strong>&nbsp;</strong></p> <ol start="13"> <li><strong> November 2014: Breast Cancer Awareness workshop and rally: Organizing Secretary</strong></li> </ol> <p><strong>&nbsp;</strong></p> <ol start="14"> <li><strong>9th November 2014: Carcinoma Ovary Panel organized by FOSGI: Moderator of Panel on ovarian cancer.</strong></li> </ol> <p><strong>&nbsp;</strong></p> <ol start="15"> <li><strong>8th November 2014: Lung Cancer Symposium interdepartmental at AIIMS, Patna: Organizer as well as delivered a talk.</strong></li> </ol> <p><strong>&nbsp;</strong></p> <ol start="16"> <li><strong>12th December 2014: Imaging and prognosis of cervical cancer by international Faculty , Dr. Kailash Narayan, Head Gynec-Oncology, Peter, Mac Cullum Cancer Centre, Melbourne, Australia: Organizer and Moderator of interactive session.</strong></li> </ol> <p><strong>&nbsp;</strong></p> <ol start="17"> <li><strong>27th February – 1st March 2015, “XIIIth Annual Conference on Evidence Based Management of Cancers in India- Modern Radiation Oncology Practice”: Participated as Delegate. 13th – 15th </strong></li> </ol> <p><strong>&nbsp;</strong></p> <ol start="18"> <li><strong>March, 2015, 32nd conference of Indian Cooperative Oncology Network (ICON) in Patna: Organizing committee Member. And Panellist as well as Chairperson for the same.</strong></li> </ol> <p><strong>&nbsp;</strong></p> <ol start="19"> <li><strong>29th March: Friends of Max, Patient survivor meet at Patna Museum: Invited Faculty.</strong></li> </ol> <p>&nbsp;</p> <p><strong><em>&nbsp;</em></strong></p> <ol start="20"> <li><strong><em>14th April 2018: Society of Oncology, Bihar Annual Conference.” Role of Targeted therapy in colorectal cancer</em></strong></li> </ol> <p>&nbsp;</p> <ol start="21"> <li><strong><em>29th July 2018: "Best of American Society of Clinical Oncology (ASCO) Conference", New Delhi Abstract 10527: Intravenous fosaprepitant for the prevention of chemotherapy induced vomiting in children: A double blind placebo controlled, phase III randomized trial.</em></strong></li> </ol> <p><strong><em>&nbsp;</em></strong></p> <ol start="22"> <li><strong><em>1st - 2nd September2018: Delivered a talk on Meta-analysis on Gastric Cancer in the Indian college of Radiation Oncology (ICRO) teaching Programme at V N Cancer Centre G. Kuppuswami Naidu Memorial Hospital Coimbatore.</em></strong></li> </ol> <p><strong><em>&nbsp;</em></strong></p> <ol start="23"> <li><strong><em>16th -18th November 2018: BISICON: 6th Annual Conference of Breast Imaging society of India delivered talks on:</em></strong></li> <li><strong><em>a) Non-surgical Management of Breast Cancer.</em></strong></li> <li><strong><em>b) Let The Lady Speak – Breast cancer survivors and Doctors.</em></strong></li> <li><strong><em>c) Clinical breast self </em></strong></li> </ol> <p><strong><em>&nbsp;</em></strong></p> <ol start="24"> <li><strong><em>2nd December 2018: XXVI BOGSCON: Annual Bihar Obstetrics &amp; Gynecology society conference. Invited as Faculty and gave a talk on Management of Vulval Cancers.</em></strong></li> </ol> <p><strong><em>&nbsp;</em></strong></p> <ol start="25"> <li><strong><em>8th December 2018: 8th Bihar chapter IAPSM Conference at IGIMS. Invited as Faculty and delivered a Talk on HPV Vaccines- An Enigma or Reality?</em></strong></li> </ol> <p>&nbsp;</p> <p><strong>&nbsp;</strong></p> <p><strong>&nbsp;</strong></p> <p><strong>Publications </strong></p> <p><strong>&nbsp;</strong></p> <p><strong>&nbsp;</strong></p> <p>&nbsp;</p> <ol> <li>Mandal A, Singh P, Bera S, et al. Set-up Errors and Determination of Planning Target Volume Margins Protocol for Different Anatomical Sites in a Newly Established Tertiary Radiotherapy Centre in India. Asian J Oncol. April 2020. doi:10.1055/s-0040-1710146</li> </ol> <p>&nbsp;</p> <ol start="2"> <li>Singh D, Singh P, Mandal A, Epidemiology and Treatment Outcomes of Testicular Germ Cell Tumor at Tertiary Care Center in Patna, India: A Retrospective Analysis. Vol 5; 2020.</li> </ol> <p>&nbsp;</p> <ol start="3"> <li>Singh D, Singh P; primary small cell carcinoma of breast, rare breast cancer: a case report; international journal of scientific research; Volume-9 | Issue-2 | February-2020 | PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr</li> </ol> <p>&nbsp;</p> <ol start="4"> <li>Saxena AK, Singh V, Aprajita, Kumar A, Tiwari M, Singh Pritanjali et al. (2019) Stop Codons of TGF βRI Gene Modulate the Functional Activity of 3DStructure and their Genetic Susceptibility in the Case of Wilms’ Tumour. J Cancer Sci Ther 11: 251-255.</li> </ol> <p>&nbsp;</p> <ol start="5"> <li>Singh P, Singh A, Singh V P. Unusual case of metastasis of urinary bladder Transitional cell carcinoma to the gingiva. JMSCR Vol |07| Issue |06| Page 1043-1046 |June.</li> </ol> <p>&nbsp;</p> <p>&nbsp;</p> <ol start="6"> <li>Yadav RK, Ali A, Kumar S, Alpana Sharma, Basab Baghchi, Pritanjali Singh, Sushmita Das, Chandramani Singh, and Sadhana Sharma CAR T cell therapy: newer approaches to counter resistance and cost. Heliyon. 2020;6(4):e03779. Published 2020 Apr 16. doi:10.1016/j.heliyon.2020.e03779</li> </ol> <p>&nbsp;</p> <ol start="7"> <li>Singh P, Singh R. Evaluation of Quality of life of Breast Cancer patients During Adjuvant Treatment at a Tertiary Care Teaching Hospital ;Int J Med Res Prof 2018 July;4(4);228-31.</li> </ol> <p>&nbsp;</p> <p>&nbsp;</p> <ol start="8"> <li>Singh P, Deep A. A cross Sectional Study Determining the Knowledge and Awareness about Breast Cancer Amongst Females: An Institutional Based Study; Int J Med Res Prof. 2018 May, 4(3); 227-230.</li> <li>Jhoshi R, Singh P,Shrestha D.B. Primary Hepatic Lymphoma: A Complex and Challenging Diagnosis MJSBH Vol 16 Issue 1; Pg 54-57 Jan-June 2017.</li> </ol> <p>&nbsp;</p> <ol start="10"> <li>P Singh;Minimal Invasive methods used in Radiation Oncology: Progress in minimal invasive surgery. (APSCON) 2015</li> </ol> <p>&nbsp;</p> <p>&nbsp;</p> <ol start="11"> <li>Singh V P, Singh P: Chapter on Breast cancer Screening: Current Status of Screening in Obstretrics &amp; Gynecology management of Abnormality by Jaypee Brothers1 (e) published in 2015.</li> </ol> <p>&nbsp;</p> <ol start="12"> <li>Prasad R R, Singh P, Report of chronic myeloid leukemia from Indira Gandhi Institute of Medical Sciences, Regional Cancer Center, 2002-2009. Indian Journal of Medical and Paediatric Oncology, Vol. 34, No. 3, July-September, 2013, pp. 172-174.</li> </ol> <p>&nbsp;</p> <p>&nbsp;</p> <ol start="13"> <li>Singh P, Prasad R R ,Experience of organ preservation in urinary bladder:3292 Abstract Book, a supplement to the official ESMO journal Annals of Oncology 2012.</li> </ol> <p>&nbsp;</p> <ol start="14"> <li>Prasad R R, Singh P, Low dose gemcitabine and radiotherapy in Skin metastasis. Abstract accepted in Annuals of Oncology Aug 2010.</li> </ol> <p>&nbsp;</p> <p>&nbsp;</p> <ol start="15"> <li>Munshi A, Singh P; Tamoxifen in breast cancer: Not so easy to write off. A. The Breast, Apr; 17(2):121-4. Epub 2007 Oct 17.</li> </ol> <p>&nbsp;</p> <ol start="16"> <li>Jalali R, Singh P , Menon H, Gujral S; Unexpected case of aplastic aneamia in a patient of Glioblastoma multiforme being treated with Temozolamide.J Neurooncol (2007) 85:105-107.</li> </ol> <p>&nbsp;</p> <p>&nbsp;</p> <ol start="17"> <li>Munshi A, Singh P “Trastuzumab:Is the new evidence revolutionary ? J Cancer Res Ther September 2006 vol 2 issue 3 pg: 144-146.</li> <li>Singh P. “Management of CML-Post imatinib era”.Patna Journal of Medicine.Vol (79), 2005.</li> </ol> <p>&nbsp;</p> <p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TRIALS / PROJECTS</strong></p> <p><strong><u>&nbsp;</u></strong></p> <p><strong>Dr. Pritanjali Singh as Investigator/SUB<u>/CO INVESTIGATOR</u>.</strong></p> <p><strong>&nbsp;</strong></p> <p>&nbsp;</p> <ol> <li>A Radomised, Double-blind, Multicentre phase II/III study to compare the efficacy of Cediranib (RECENTIN™, AZD2171) in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) , to the efficacy of Bevacizumab in combination with FOLFOX in patients with previously untreated Metastastic Colorectal Cancer”.</li> </ol> <p>&nbsp;</p> <ol start="2"> <li>A phase III, Double- Blind, placebo-Controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with Pemetrexed + Cisplatin for advanced nonsquamous Non- Small Cell Lung Cancer.</li> </ol> <p>&nbsp;</p> <ol start="3"> <li>A Phase III study of Vinflunine plus capecitabine versus capecitabine alone&nbsp;&nbsp; in&nbsp; patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant.</li> </ol> <p>&nbsp;</p> <p>4) A pilot study on factors influencing&nbsp;&nbsp; health seeking&nbsp;&nbsp; behavior&nbsp;&nbsp; of women with breast cancer at tertiary health care center AIIMS, PATNA. (Co-Investigator)</p> <p>&nbsp;</p> <p>5) Management of Wilms Tumour: A single institution based study. (Principal Investigator)</p> <p>&nbsp;</p> <p>6) A collaborative Protocol for Newly diagnosed Indian Hodgkin’s Lymphoma Patients: (INPOG –HL-15-01) National Multicenter study with AIIMS, Patna as one of the few participating centers. (Principal Investigator)</p> <p>&nbsp;</p> <p>7) Hospital Based Cancer Registry in collaboration with NCDIR-NCRP, Bangalore.(Principal&nbsp; Investigator for AIIMS, Patna).</p> <p>review</p> <p>&nbsp;</p> <p>&nbsp;8) “Adjuvant Chemotherapy or Chemo radiation in Gall Bladder Cancer: A phase III Randomized controlled study (ACCeleRate Trial).” Multicentric study&nbsp; (Principal Investigator for AIIMS, Patna).&nbsp;&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;9) “Study to assess compliance to National Cancer grid guideline for Cervix Cancer.” (Principal Investigator for AIIMS, Patna).&nbsp;&nbsp;</p> <p>&nbsp;</p> <p>10) A Collaborative Protoccol For Newly Diagnosed Indian Childhood Lymphoma Patients (IMPOG HL-15-01)&nbsp; (Principal Investigator for AIIMS, Patna).&nbsp;&nbsp;</p> <p>&nbsp;11) Management of Wilms Tumour: A single institution based study. (Principal Investigator for AIIMS, Patna).</p> <p>&nbsp;</p> <p>&nbsp;12) Hospital Based Cancer Registry in collaboration with NCDIR-NCRP, Bangalore.&nbsp; (Principal Investigator for AIIMS, Patna).</p> <p>&nbsp;</p> <p>&nbsp;13) Determinants of prognosis in B-cell malignancies receiving CAR T-cell therapy. (Co investigator)</p> <p>&nbsp;</p> <p>&nbsp;14) National Cancer Grid survey for Gall Bladder Cancer (Co investigator)</p> <p>&nbsp;</p> <p>15) ACCESS INDIA STUDY A Multi-Centre Study of Accessing Childhood Cancer Services in India (InPOG-ACC-16-02) , PI oft AIIMS Patna.</p> <p>&nbsp;</p> <p><strong>&nbsp;</strong></p> <p><strong>&nbsp;</strong></p> <p><strong>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</strong>MEMBERSHIP OF PROFESSIONAL ASSOCIATIONS</p> <p><strong><u>&nbsp;</u></strong></p> <p>1) Life membership of Association of Radiation Oncologists of India. (AROI)</p> <p>&nbsp;</p> <p>2) Indian Association of Hyperthermic Oncology and Medicine (IAHOM): Student Member</p> <p>&nbsp;</p> <p>3) Life member of Bihar State Chapter and Maharastra State Chapter (AROI).</p> <p>&nbsp;</p> <ul> <li>Life member, Society of Oncology, Bihar.</li> </ul> <p>&nbsp;</p> <ul> <li>Life member of Association of Gynecology Oncology of India.</li> </ul> <p>&nbsp;</p> <ul> <li>Life member of Indian Federation of Head and Neck Oncology.</li> </ul> <p>&nbsp;</p> <ul> <li>Life member of ICRO: Indian College of Radiation Oncology.</li> </ul> <p>&nbsp;</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p><strong>&nbsp;</strong><strong><u>Highlights of Achievement at AIIMS, Patna:</u></strong></p> <p>The Radiation Oncology Department AIIMS, Patna is committed to being at the forefront of finding better treatments and cures for cancer through its superior clinical care and clinical trials coupled with cutting edge research in cancer biology, medical physics, and health services. With enrolment of more faculties, Residency training programs will aim to train leaders in radiation oncology.&nbsp; Departmental mission will be to practice the patient-centred care treatment paradigm; to sustain growth in academic programs and strengthen community partnerships; to innovate, develop, and translate new treatments and cures for cancer; and to foster leadership development in the field of radiation oncology. Free cancer screening and awareness camps and rallies being organised on a regular basis, such as breast cancer awareness and health check-up week between 2/2/15-7/2/15 to mark the World Cancer Day.Set up the Department of Radiation Oncology at AIIMS Patna with World Class Elekta Versa HD,GE Simulator, Microselectron HDR . Started Postgraduate Teaching .</p> <p>&nbsp;</p> <p><u>Education:</u></p> <p>1) Presently teaching nursing staff regarding chemotherapy drug infusion and extravasation.</p> <p>2)&nbsp; Ward Teaching of MBBS Students as well as lectures on Gynaecological Malignancies.</p> <p>3) Providing Lectures regarding Nuclear Terrorism in Quick Medical Response Training Program.</p> <p>4) Postgraduate Teaching.</p> <p><u>&nbsp;Administration:</u></p> <p>Member: Purchase Committee of All India Institute of Medical Science.</p> <p>Chairman – Internal Complaints committee, AIIMS Patna.</p> <p>&nbsp;</p> <p>Dr Pritanjali Singh,</p> <p>Additional Professor,</p> <p>Radiation Oncology,</p> <p>All India Institute of Medical Sciences, Patna.</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p>
All India Institute of Medical Sciences, Patna

Dharmendra Singh
<p><strong>Name: DHARMENDRA SINGH</strong></p> <p><strong>Father’s Name:&nbsp; CHANDRADEEP SINGH</strong></p> <p><strong>Address&nbsp;&nbsp; : Dharmendra Singh, C/O Ravindar Sharma, Cheddi Tola, Nikunj Police Colony, Phulwarisharif, Near AIIMS, Patna, Pin 801507.</strong></p> <p><strong>Date of Birth: 15<sup>th</sup> September 1984.</strong></p> <p><strong>Nationality: Indian </strong></p> <p><strong>Marital status: Married </strong></p> <p><strong>Educational Qualification:</strong></p> <table> <tbody> <tr> <td width="163"> <p><strong>Degree</strong></p> </td> <td width="120"> <p><strong>University</strong></p> </td> <td width="126"> <p><strong>Institution</strong></p> </td> <td width="132"> <p><strong>Passing Year</strong></p> </td> <td width="115"> <p><strong>% Marks</strong></p> </td> </tr> <tr> <td width="163"> <p>M.B.B.S.</p> </td> <td width="120"> <p>WBUHS</p> </td> <td width="126"> <p>IPGME&amp;R, Kolkata</p> </td> <td width="132"> <p>2011</p> </td> <td width="115"> <p>63.3</p> </td> </tr> <tr> <td width="163"> <p>M.D (Radiotherapy)</p> </td> <td width="120"> <p>WBUHS</p> </td> <td width="126"> <p>IPGME&amp;R, Kolkata</p> </td> <td width="132"> <p>2017</p> </td> <td width="115"> <p>67.1</p> </td> </tr> </tbody> </table> <p><strong>&nbsp;</strong></p> <p><strong>Internship&nbsp; &nbsp;: Completed&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p> <p><strong>Duration&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; from 23<sup>rd</sup> March 2011 to 22<sup>nd</sup> March 2012.</strong></p> <p><strong>Experience:</strong></p> <table width="672"> <tbody> <tr> <td width="155"> <p><strong>Designation</strong></p> </td> <td width="138"> <p><strong>Department</strong></p> </td> <td width="132"> <p><strong>Institute</strong></p> </td> <td width="126"> <p><strong>From</strong></p> </td> <td width="121"> <p><strong>Upto</strong></p> </td> </tr> <tr> <td width="155"> <p>Junior Resident</p> </td> <td width="138"> <p>Ophthalmology</p> </td> <td width="132"> <p>IPGME&amp;R, Kolkata</p> </td> <td width="126"> <p>April 2012</p> </td> <td width="121"> <p>March 2013</p> </td> </tr> <tr> <td width="155"> <p>Junior Resident</p> </td> <td width="138"> <p>Medicine</p> </td> <td width="132"> <p>IQ City Medical College, Durgapur</p> </td> <td width="126"> <p>April 2013</p> </td> <td width="121"> <p>May 2014</p> </td> </tr> <tr> <td width="155"> <p>Specialist Medical Officer</p> </td> <td width="138"> <p>Radiotherapy</p> </td> <td width="132"> <p>IPGME&amp;R, Kolkata</p> </td> <td width="126"> <p>August 2017</p> </td> <td width="121"> <p>August 2018</p> </td> </tr> <tr> <td width="155"> <p>Senior Resident</p> </td> <td width="138"> <p>Radiotherapy</p> </td> <td width="132"> <p>AIIMS, Patna</p> </td> <td width="126"> <p>August 2018</p> </td> <td width="121"> <p>Contd.</p> </td> </tr> </tbody> </table> <p><strong>&nbsp;</strong></p> <p><strong>Interests:</strong></p> <p>Oncology (Breast Cancer, Cervical Cancer, Head &amp; Neck Cancer)</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medical Oncology,</p> <p>Human Physiology,</p> <p>Neurology</p> <p><strong>Papers Published: </strong></p> <p><strong>Case Report </strong></p> <ol> <li>Multifocal Extraskeletal&nbsp; Myxoid&nbsp; Chondrosarcoma Volume : IV, Issue : XII, December – 2015 International Journal of Scientific Research, Journal DOI : 10.15373/22778179</li> <li>Primary Small Cell Carcinoma of Breast, Rare Breast Cancer: A Case Report. February 2020; International Journal of Scientific Research&nbsp;9(2):6-7</li> </ol> <p><strong>Research Articles</strong></p> <p>&nbsp;</p> <ol> <li>Epidemiology and treatment outcomes of testicular germ cell tumor at tertiary care center in Patna, India: A retrospective analysis. Asian Pacific Journal of Cancer Care <strong>2020-02-15&nbsp;|&nbsp;journal-article DOI:&nbsp;</strong><a href=""><strong>10.31557/apjcc.2020.5.1.45-50</strong></a></li> </ol> <p>&nbsp;</p> <ol> <li>Epidemiology, Pattern of Recurrence and Survival in Triple-negative Breast Cancer. Asian Pacific Journal of Cancer Care <strong>2020-06-07&nbsp;|&nbsp;journal-article, DOI:&nbsp;</strong><a href=""><strong>10.31557/apjcc.2020.5.2.87-94</strong></a></li> </ol> <p>&nbsp;</p> <ol> <li>The prognostic value of lymph node ratio in survival of non-metastatic breast carcinoma patients; Breast Cancer Research and Treatment; <strong>2020-08-27&nbsp;|&nbsp;journal-article; DOI:&nbsp;</strong><a href=""><strong>10.1007/s10549-020-05885-y</strong></a></li> </ol> <p>&nbsp;</p> <ol> <li>Clinical Characteristics and Treatment Outcomes of Patients with Ovarian Germ Cell Tumor Treated at a Tertiary Care Center in Patna, India; Indian Journal of Gynecologic Oncology; <strong>2020-09&nbsp;|&nbsp;journal-article; DOI:&nbsp;</strong><a href=""><strong>10.1007/s40944-020-00401-y</strong></a></li> </ol> <p>&nbsp;</p> <ol> <li>Patterns of Care of Gallbladder Cancer During the COVID-19 Pandemic: An Experience of Tertiary Care Centre at Patna, India; August 2020; Asian Pacific Journal of Cancer Care&nbsp;5(S1):51-57; DOI:&nbsp;<a href=""><strong>10.31557/APJCC.2020.5.S1.51</strong></a></li> </ol> <p>&nbsp;</p> <ol> <li>The incidence of hypothyroidism in patients of head and neck carcinoma treated with radiotherapy and added risk of hypothyroidism with the addition of chemotherapy; September 2020; Journal of radiotherapy in practice; DOI: <strong><u>10.1017/S1460396920000692</u></strong></li> </ol> <p>&nbsp;</p> <p><strong>Hobbies:&nbsp; </strong>Watching documentary, Music, Reading mythological books</p> <p><strong>Contact: 9433325398</strong></p> <p><strong>Email: </strong><a href="mailto:babu.dsingh.singh35@gmail"><strong>babu.dsingh.singh35@gmail</strong></a></p> <p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><a href=""><strong></strong></a></p> <p><strong>&nbsp;</strong></p> <p>&nbsp;</p> <p>&nbsp;</p>
Affiliation not stated

Manika Verma
<p><br>PERSONAL DETAILS:<br>Name: Dr. Manika Verma<br>Date of Birth: 17th April, 1990<br>Languages known: Hindi and English<br>Present Address: W/O Dr. Ravi Kant Narayan,<br> Flat No. 111, 1st Floor, Palm Building, Anand green Apartments,<br> Khagaul Road, Phulwarisharif, Patna -801505, Bihar.<br>Permanent Address: W/O Dr. Ravi Kant Narayan,<br> Flat No. 6 C, Jyoti Vihar Apartment,<br> Near Kishoreganj chowk, Harmu Bypass road,<br> Ranch- 834001, Jharkhand.<br>Father’s Name: Dr.AmarVerma<br>Marital Status: Married<br>Husband’s Name: Dr. Ravi kant Narayan<br>Mobile: 9643934890<br><br>No. Degree/Diploma Institution Years attended Place Remarks<br>1. Diplomat of National<br>Board (DNB)<br>Rajiv Gandhi Cancer Institute<br>and Research centre<br>April 2015 –<br>April 2018<br>New Delhi Cleared<br>2. M.B.B. S Rajendra Institute of Medical<br>Sciences (R.I.M.S)<br>August 2007 –<br>September 2012<br>Ranchi First<br>Division<br>3. Senior School<br>Certificate (C.B.S.E)<br>D.A.V, JawaharVidya<br>Mandir, Shyamali<br>June 2005 –<br>March 2007<br>Ranchi First<br>division<br>4. Indian School<br>Certificate Examination<br>(I.C.S.E)<br>St. Joseph’s Convent High<br>School<br>1996-2005 Patna First<br>division<br>CIRRICULUM VITAE<br>ACADEMIC QUALIFICATIONS<br>THESIS COMPLETED<br>“Prospective Comparative Randomised Study Comparing Two Pre-Operative Chemo-radiotherapy Schedules in<br>Middle and Lower Third Carcinoma Oesophagus.”<br>PUBLICATIONS<br>1. Narayan RK, Kumari S, Verma M. Prevalence and variety of Sutural bones in densely populated<br>East Indian state of Bihar. Ann. Acad. Med. Siles. 2019; 73: 174–181. DOI: 10.18794/aams/109153.<br>2. Kumari S, Verma M, Narayan RK. Role of clavicle curvatures in fracture stabilisation: a study in<br>east Indian population. Int J Anat Res. 2018;6(4.1):5811-14.<br>3. Dr. A.Verma, Dr.Binita Nancy Khalkho, Dr. A. Verma, Dr. Manika Verma, Dr. Ravi Kant<br>Narayan. Spectrum of Neonatal Sepsis in NICU. IOSR-JDMS, 2017; 16(4): 11-4. DOI:<br>10.9790/0853-1604101114<br>4. A. Verma, A. Verma, Ravi Kant Narayan, Manika Verma. Random Sample Survey of Knowledge,<br>Attitude and Practices (KAP) About Tuberculosis Among Parent of Category -I Pediatric Patients.<br>IOSR-JDMS, 2017; 16(10): 35-40. DOI: 10.9790/0853-1610033540<br>5. Verma A, Sandhya K, Verma M, Narayan RK. Recent developments in management of a child with<br>Down Syndrome, International Journal Dental and Medical Sciences Research, 2017; 1(1):1-5.<br>CHAPTERS:<br>1. Narayan R.K., Verma M. (2019) Encephalization. In: Vonk J., Shackelford T. (eds) Encyclopedia of<br>Animal Cognition and Behavior. Springer, Cham.<br>2. Narayan R.K., Verma M. (2019) Cranial Base. In: Vonk J., Shackelford T. (eds) Encyclopedia of<br>Animal Cognition and Behavior. Springer, Cham.<br>1. Internship of 1 year in Rajendra Institute of Medical Sciences, Ranchi, Jharkahand from September 2012<br>– September 2013.<br>2. Junior Resident (NON- ACAD) for 8 months from July 2014 – April 2015 in Department of Emergency<br>Medicine, Rajendra Institute of Medical Sciences, Ranchi, Jharkahand<br>3. Junior Resident/DNB trainee (Academic) for 3 years from April 2015 to April 2018 in Department of<br>Radiation oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi.<br>4. Nine (Dec. 2018 – August 2019) months as Senior resident (S. R.) in Department of Radiotherapy at<br>Mahveer Cancer Sansthan, Patna<br>5. Currently working as Senior resident (S. R.) (September 2019 – till date) in Department of Radiotherapy<br>at AIIMS, Patna<br>RESEARCH EXPERIENCE<br>CLINICAL EXPERIENCE<br>1. Participated in 3rd Annual Conference AROI – Bihar Chapter at Patna, Bihar in June 2019.<br>2. Participated in VIth national Conference of Young Radiation Oncologists of India on management of<br>loco-regional recurrences and re-irradiation at New Delhi in 2018.<br>3. Participated in 22nd Annual conference of Breast Cancer Foundation, India in 2018 at Haryana.<br>4. Participated in RGCON 2016,2017 and 2018.<br>5. Participated in International Symposium on molecular Oncology and translational cancer research, The 3<br>B’s- Bench, Bedside and Business at New Delhi in 2017.<br>6. Participated in 4th Masterclass on Evidence based management of thoracic malignancies at New Delhi in<br>2017.<br>7. Participated in Lymphoma Update – 2016 as a delegate at New Delhi in 2016.<br>8. Participated in Osteosarcoma update -2016 at new Delhi in 2016.<br>9. Participated in evidence based Max Debates in oncology at New Delhi in 2015.<br>10. Participated in 50th national conference of Indian Academy of Paediatrics in Kolkata in 2013.<br>11. Participated in 49th national conference of Indian Academy of Paediatrics in Haryana in 2012<br>12. Participated in CME on Epidemic and Pandemic preparedness and response in 2012 at R.I.M.S, Ranchi.<br>1. Workshop on Breast Cancer Radiation at AIIMS, Patna on 10th October 2019.<br>2. Attended 1 month observership at Post Graduate Institute, Chandigarh, working on cobalt based<br>treatment machines, Linear accelerators, HDR and Cobalt based brachytherapy, Gamma Knife surgery<br>and chemotherapy from Feb – Mar 2017.<br>3. Workshop on Thesis Research &amp; Protocol writing conducted by IIPH in July 2015 at New Delhi.<br>4. Participated in PubMed basics training program by Q-Med Knowledge foundation in 2011 at R.I.M.S,<br>Ranchi.<br>1. Association of Radiation Oncologists of India (AROI).<br>2. North zone Association of Radiation Oncologists of India (NZ-AROI).<br>1. Indian Council of Medical Research (I.C.M.R) certification for Short term studentship in 2010 on<br>“INCIDENCE AND CLINICAL MANIFESTATIONS OF SEVERE COMPLICATED MALARIA<br>IN PAEDIATRIC AGE GROUP IN A TERTIARY CARE HOSPITAL OF JHARKHAND,<br>R.I.M.S, RANCHI.”<br>CONFERENCE &amp; CME ATTENDED<br>WORKSHOP &amp; TRAINING PROGRAM<br>MEMBERSHIP<br>AWARDS<br>For References –<br>Dr. Kundan S. Chufal,<br>Sr. Consultant,<br>Dept. of Radiation Oncology,<br>Rajiv Gandhi Cancer Institute and Research Centre, New Delhi.<br>Mobile No. -9811996326<br>Dr. Anjali K. Pahuja,<br>Consultant,<br>Dept. of Radiation Oncology,<br>Rajiv Gandhi Cancer Institute and Research Centre, New Delhi.<br>Mobile no. - 8447183013<br>DECLARATION<br>I hereby declare that above mentioned particulars are true to the best of my knowledge and<br>belief.<br>Date:<br>Place:<br>Dr. Manika Verma<br>Senior Resident<br>Department of Radiotherapy<br>All India Institute of Medical Sciences, Patna</p>
All India Institute of Medical Sciences ,Patna

Amrita Rakesh
<p>Dr. AMRITA RAKESH<br><br>WORK EXPERIENCE</p> <p>INTERNSHIP<br>APRIL 2014 – MARCH 2015<br>*completed one year of Compulsory Rotatory Internship from Dr.Ram Manohar Lohia<br>Combined Hoapital,Lucknow.<br>* I duly attended all the postings in all the departments and gave my maximum there to<br>learn new things.<br>* worked equally in both the day and night shift<br>MEDICAL OFFICER at Medanta , The medicity , Gurgaon<br>JANUARY 2016 TO MARCH 2016.<br>I worked with the cardiology unit at Medanta,Gurgaon, and thereafter i<br>was selected for the postgraduate DNB course through ALL INDIA MD/<br>Contact – 7665021112<br>Address- house no-63, road no-1 , Friends Colony ,<br>P.O- Ashiana Nagar, Patna- 800025 (Bihar) .<br>E-Mail-<br>MS/DNB entrance examinations held in December, 2015 and secured an<br>All India Rank of 5000.<br>DNB TRAINING<br>22nd MARCH 2016 – 21st March 2019<br>*completed 3 yrs of compulsory postgraduate training in the department of Radiotherapy,<br>Bhagwan Mahaveer cancer hospital and research centre(BMCHRC), Jaipur , with<br>rotation in departments of medical oncology and surgical oncology.<br>*good experience with Cobalt, 3DCRT, IMRT, IGRT &amp; VMAT.<br>*Independently able to discharge Brachytherapy procedures including ICRT &amp; CVS.<br>*Performed under guidance of senior consultant SRS, SBRT &amp; MUPIT.<br>*I duly accomplished all the duties assigned and attended all the postings in all the<br>departments and gave my maximum there to learn new things.<br>* worked equally in both the day and night shift<br>SENIOR RESIDENT, DEPARTMENT OF RADIOTHERAPY ,<br>BMCHRC, JAIPUR<br>April 2019 to July 2019<br>Thereafter i was selected for SR at AIIMS,Patna.<br>SENIOR RESIDENT, DEPARTMENT OF RADIOTHERAPY<br>AIIMS,PATNA — JULY 2019 to PRESENT.<br>EDUCATION<br>1. D.N.B (Radiotherapy)<br>22nd MARCH 2016 - 21st MARCH 2019<br>I had cleared my DNB THEROY exam held in Dec, 2018 &amp; DNB PRACTICAL<br>exam (march 2019) in 1st attempt itself.<br>2. M.B.B.S<br>AUGUST 2009 – JANUARY 2014<br>*Completed my MBBS from Moti Lal Nehru Medical College, Allahabad, affiliated under the<br>Reputed King George Medical University,Lucknow.<br>*Took admission through the then held AIPMT 2009 conducted by CBSE and secured an All<br>India Rank 813.<br>* performed well throughout my MBBS and secured over all 66.7% .<br>2. ALL INDIA SENIOR SCHOOL SECONDARY EXAMINATIONS<br>MARCH 2007<br>• Attended high school from Kendriya Vidyalaya,Bailey road .<br>• Secured 85%<br>3. ALL INDIA SECONDARY SCHOOL EXAMINATIONS<br>MARCH 2005<br>• Attended secondary school from D.A.V. Public School,Khagaul.<br>• Secured 91.6%<br>THESIS (APPROVED BY NBE)<br>• A COMPARATIVE STUDY OF PLANNING AND DOSIMETRY IN LOCALLY<br>ADVANCED HEAD AND NECK CANCER - SEQUENTIAL VERSUS<br>SIMULTANEOUS INTEGRATED BOOST METHODS IN INTENSITY MODULATED<br>RADIOTHERAPY.<br>PUBLISHED ARTICLES :<br>1. Depression in cancer patients: Magnitude of problem and factors<br>responsible<br>January 2019Indian journal of medical and paediatric oncology 40(4):542<br>DOI: 10.4103/ijmpo.ijmpo_99_18<br>Kartick Rastogi, Amrita Rakesh, Subhash Chand Bairwa, Sandeep Bhaskar, Shivani Gupta,<br>Shantanu Sharma, Sandeep Jain<br>2. Set-up Errors and Determination of Planning Target Volume Margins<br>Protocol for Different Anatomical Sites in a Newly Established Tertiary<br>Radiotherapy Centre in India<br>April 2020<br>DOI: 10.1055/s-0040-1710146<br>Avik Mandal Pritanjali Singh Soumen Bera Avajeet Kumar Dharmendra Singh Manika<br>Verma Amrita Rakesh Arkaprava Sinha</p>
All India Institute of Medical Sciences, Patna

How to Cite

Mandal, A., Singh, P., Singh, D., Verma, M., & Rakesh, A. (2021). Impact of COVID Pandemic on Cancer Care: Cross-sectional Scenario of an Indian State (Bihar). Asian Pacific Journal of Cancer Care, 6(S1), 27-33.

HTML Before

HTML After

  • Abstract viewed - 51 times
  • PDF (FULL TEXT) downloaded - 18 times
  • XML downloaded - 0 times